Can Adalimumab treat ankylosing spondylitis?

Adalimumab (Adalimumab) is indicated for the relief of the signs and symptoms of adult patients with active ankylosing spondylitis. Ankylosing spondylitis is a chronic inflammatory joint disease that primarily affects the spine and pelvic region. It causes joint stiffness, pain, and dysfunction in the spine and pelvis. Adalimumab is a biologic agent that is a tumor necrosis factor-alpha (TNF-α) monoclonal antibody that reduces symptoms by inhibiting the effects of this inflammatory mediator. Clinical studies have confirmed that adalimumab is very effective in the treatment of ankylosing spondylitis. It can significantly reduce pain, improve joint mobility, and reduce joint inflammation and damage.